IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
IO Biotech has raised $6.6M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2025.
IO Biotech's investors include European Investment Bank, RA Capital Management, Vivo Capital, Novo Nordisk, Samsara BioCapital.
IO Biotech is headquartered in Copenhagen, Denmark.
IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
IO Biotech is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"IO Biotech — Funding & Investors." VCBacked, September 30, 2025, https://www.vcbacked.co/company/io-biotech. Accessed July 20, 2026.
VCBacked. (2025). IO Biotech — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/io-biotech
{{cite web |title=IO Biotech — Funding & Investors |url=https://www.vcbacked.co/company/io-biotech |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated